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Essentials
• Molecular diagnostics has improved the differentiation
of acute thrombotic microangiopathys (TMAs).
• Atypical hemolytic uremic syndrome may have features
mimicking thrombotic thrombocytopenic purpura.
• We identified novel complement mutations and a high
incidence of CD46, with favorable long term outcomes.
• Complement mutation analysis in TMA where the diag-
nosis is unclear and ADAMTS-13 activity is >10%.
Summary. Background: Differentiation of acute throm-
botic microangiopathy (TMA) at presentation has
historically been dependent on clinical parameters. Con-
firmation of thrombotic thrombocytopenic purpura (TTP)
is increasingly reliant on demonstrating deficient
ADAMTS-13 activity. The identification of alternative
complement pathway abnormalities in atypical hemolytic
uremic syndrome (aHUS), along with the proven efficacy
of terminal complement inhibitors in treatment, has
increased the need for rapid differentiation of TTP from
aHUS. Objectives: We describe the clinical phenotype and
nature of complement mutations in a cohort of aHUS
patients referred as acute TMAs. Patients/methods: Four-
teen consecutive aHUS patients were screened for
mutations in C3, CD46, CFH, CFI, and CFB, as well as
factor H (FH) antibodies. All aHUS patients had
ADAMTS-13 activity > 10%. Results: Of 14 aHUS
patients, 11 (79%) had platelet counts < 30 9 109/L dur-
ing the acute phase. Median presenting creatinine level
was 295 lmol L1, while five (36%) of 14 presented with
a serum creatinine level < 200 lmol L1. Alternative
complement pathway mutations were detected in 9 (64%)
of 14 patients, including CD46 mutations in five (36%) of
14 patients. Patients were identified with novel mutations
in CFB and C3 that have not been previously reported.
Conclusions: We demonstrate that diagnostic differentia-
tion based on platelet count and renal function is insuffi-
cient to predict an underlying complement mutation in
some aHUS cases. Specifically, we demonstrate a high
frequency of functionally significant CD46 mutations
which may mimic TTP. ADAMTS-13 activity > 10% in a
patient with a TMA should necessitate genetic screening
for complement abnormalities.
Keywords: atypical hemolytic uremic syndrome; CD46;
complement; diagnosis; thrombotic thrombocytopenic
purpura.
Introduction
Atypical hemolytic uremic syndrome (aHUS) and throm-
botic thrombocytopenic purpura (TTP) are thrombotic
microangiopathies (TMA) that manifest with organ dys-
function or life threatening features requiring urgent
recognition and treatment. Both present with microan-
giopathic hemolytic anemia and thrombocytopenia,
although the clinical course of the two diseases can be
markedly different. Historically, ~60% of aHUS patients
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progressed to end-stage renal failure (ESRF) [1,2],
whereas in TTP, neurological and cardiac features are
often more prominent and severe renal dysfunction is
rare.
Although it is known that aHUS and TTP are histolog-
ically distinct entities [3], diagnosis is often reliant on clin-
ical features, such as the pattern of organ dysfunction
and degree of thrombocytopenia. It has been suggested
that a serum creatinine level of > 150 to 200 lmol L1 or
a platelet count of > 30 9 109 L1 ‘almost eliminates’ a
diagnosis of TTP [4]. Because the two diseases have over-
lapping clinical features, however, there is inherent oppor-
tunity for misdiagnosis, and studies on TTP and aHUS
have been open to diagnostic bias. The term ‘TTP-HUS’
has been used historically to reflect the degree of diagnos-
tic uncertainty.
The past decade has seen major advances in our
knowledge of the molecular pathophysiology underlying
both aHUS and TTP, accompanied by shifts in diag-
nostic testing and divergence of treatment algorithms
for the two diseases. In aHUS, dysregulation of the
alternative complement pathway leads to excessive acti-
vation of the terminal complement pathway, comple-
ment-mediated endothelial cell damage, and subsequent
glomerular microthrombi [2]. Detectable complement
abnormalities have been described in ~50% of patients,
including loss of function mutations within membrane
co-factor protein (CD46), complement factor H (CFH)
and factor I (CFI), and autoantibodies to the factor H
(FH) and factor I (FI) proteins. Gain-of-function
mutations have also been identified within complement
factor B (CFB) and C3 [5–7].
Thrombotic thrombocytopenic purpura, caused by an
acquired or inherited deficiency of the von Willebrand
factor–cleaving protease ADAMTS-13 (a disintegrin and
metalloproteinase with a thrombospondin type 1 motif
member 13), results in spontaneous aggregation of plate-
lets and ultralarge von Willebrand multimers to form pla-
telet-rich thrombi throughout the microvasculature [8].
Assessment of ADAMTS-13 activity is now routinely per-
formed in patients presenting with acute TMA and, when
< 10%, aids in the differentiation of TTP from other
causes of TMA [9,10].
Early initiation of either immunomodulatory therapy in
TTP [11] or complement blockade in aHUS [12] can
improve outcomes, increasing the need for prompt and
accurate differentiation between the TMAs.
We describe a retrospective cohort of aHUS patients
referred with acute TMA and clinically suspected TTP.
We highlight their presenting clinical and laboratory fea-
tures, and subsequent complement abnormalities. This
study emphasizes the clinical overlap and pivotal role of
ADAMTS-13 assessment in the differentiation of TMAs.
We also outline response to therapy and long-term out-
comes of this aHUS subgroup, before complement inhibi-
tors were available.
Patients and methods
Data were retrospectively analyzed for all patients with a
final diagnosis of aHUS managed at University College
Hospital London between January 2006 and July 2013.
Twelve patients were transferred during an acute presen-
tation with a presumptive diagnosis of TTP based on clin-
ical parameters. Two patients were referred to TTP clinic
following prior episodes of TMA to exclude a diagnosis
of congenital TTP (patients 1 and 6, Tables 1 and 2). All
patients had evidence of TMA, defined as the presence of
thrombocytopenia with microangiopathic hemolytic ane-
mia (anemia, schistocytes on blood film, reticulocytosis,
hyperbilirubinemia, elevated lactate dehydrogenase, and
negative direct antiglobulin test) [13], during their initial
presentation. Citrated blood for ADAMTS-13 levels was
taken prior to therapeutic plasma exchange (TPE).
Patients were also tested for human immunodeficiency
virus, antinuclear antibodies (ANA), lupus anticoagulant,
human chorionic gonadotropin, and fecal O157 entero-
toxin, if reporting diarrheal symptoms, on presentation.
C3 and C4 levels were measured prior to TPE. Patients
with secondary TMA, including transplant-associated
microangiopathy, active rheumatologic disease, malig-
nancy, and drug-induced TMA, were excluded.
Atypical hemolytic uremic syndrome was diagnosed
according to criteria published by the UK aHUS Rare
Diseases Group [14] and European guidelines [15], includ-
ing the presence of both TMA and acute kidney injury
[16] without ADAMTS-13 deficiency or inhibitors. One
patient underwent renal biopsy for diagnostic confirma-
tion. Two patients did not fit diagnostic criteria due to
normal renal function but were investigated due to recur-
rent TMA with normal ADAMTS-13 activity; the identi-
fication of a functionally significant mutation in one of
the aforementioned complement genes was supportive of
a diagnosis of aHUS in both patients. All analyses,
including mutation screening, were undertaken as part of
routine patient care.
We assessed whether coexisting complement mutations
were present in TTP cases and could account for
increased disease severity or renal impairment. Mutation
screening was undertaken in 14 TTP patients (ADAMTS-
13 activity < 10% and detectable anti-ADAMTS-13 IgG
auto antibodies) with either renal impairment or a severe
phenotypic presentation. Sample use was approved by the
local research ethics committee (reference 08/H0716/72).
ADAMTS-13 assays
ADAMTS-13 activity was measured by fluorescence reso-
nance energy transfer–von Willebrand factor 73 [17]. An
ADAMTS-13 level < 10% (normal range: 60–123%) was
confirmatory of a diagnosis of TTP in all selected
patients. Patients were screened for acquired IgG inhibi-
tors as previously described [18], with a normal range of
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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< 6.1% calculated as the 95th percentile of 49 normal
healthy controls.
Complement assays
C3 and C4 levels were measured by rate nephelometry
(Beckman Coulter Array 360, Ramsey, MN, USA). FH
and FI levels were measured by radioimmunodiffusion
(Binding Site, Birmingham, UK), Screening for FH
autoantibodies was undertaken using ELISA as described
previously [19]. FACS analysis of granulocytes from the
patients was performed as described previously [20].
Genetic analysis
Mutation screening of CFH [21], CFI [22], CFB [23], CD46
[24], and C3 [25] was undertaken using Sanger sequencing
as previously described. Genotyping of the following SNPs
CFH 331C>T (rs3753394), CFH c.184G>A; p.Val62Ile
(rs800292), CFH c.1204T>C; p.Tyr402His (rs1061170),
CFH c.2016A>G; p.Gln672Gln (rs3753396), CFH IVS15
543G>A intron 15 (rs1410996), CFH c.2808G>T;
p.Glu936Asp (rs1065489), CD46 652A>G (rs2796267),
CD46 366A>G (rs2796268), CD46 IVS9 78G>A
(rs1962149), CD46 IVS12 +638G>A (rs859705), and CD46
c.4070T>C (rs7144) was used to determine CFH and CD46
haplotypes [26].
Multiplex ligation–dependent probe amplification
Screening for genomic disorders affecting CFH, CFHR1,
CFHR2, CFHR3, and CFHR5 was undertaken using mul-
tiplex ligation–dependent probe amplification [26].
Analysis of CFH c.3134-5T>C variant
RNA was extracted from peripheral blood using
RNAeasy Mini kit (Qiagen, Manchester, UK). cDNA
was synthesized with SuperScript III First-Strand Synthe-
sis System (Invitrogen, Thermo Fisher Scientific, Paisley,
UK) using random hexamers and the extracted RNA as a
template. cDNA was used as a template in a polymerase
chain reaction with specific primers targeting the potential
splice-site mutation (CFH exon 20 [F-TATAA
GGCGGGTGAGCAAGT] and CFH exon 23[AACT-
GATTCACCTGTTCTCG]). Polymerase chain reaction
products were separated on a 2% TBE agarose gel and
sequenced using ABI Big Dye Terminator v3.1 on an
ABI 3500 Genetic Analyzer (Life Technologies, Thermo
Fisher Scientific).
Western blotting
Detection of potential abnormal protein products in serum
arising as a consequence of the CFH c.3134-5T>C variant
was undertaken by Western blotting. Sera was dilutedT
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1:1500, and 10 lL was electrophoresed on 6% sodium
dodecyl sulfate polyacrylamide gel electrophoresis gel and
transferred onto nitrocellulose. A polyclonal antibody
against FH (Calbiochem, Beeston, Nottingham, UK) was
used with rabbit anti-goat horseradish peroxidase (Abcam,
Cambridge, UK). Following washes in Tris-buffered saline
with Tween 20, the blot was developed using Pierce ECL
Western blotting substrate (Thermo Scientific).
Results
aHUS cases
Clinical features and laboratory parameters at presentation
are detailed in Table 1. Median age at first episode was
25.5 years (9 months to 72 years), and 43% were male. The
median presenting platelet count was 27 9 109 L1 (range
10–115), serum creatinine level was 295 lmol L1 (79–1812),
and ADAMTS-13 activity was 80.8% (47–120%). Eleven
(79%) of 14 patients had platelet counts < 30 9 109 L1 dur-
ing the acute phase (nine of 14 at presentation; Fig. 1).
Although renal involvement was more common and more
severe in the group subsequently diagnosed to have aHUS, 5
(36%) these 14 patients had a serum creatinine level <
200 lmol L1 on transfer to our center; in two patients,
serum creatinine was entirely within normal limits (Table 1,
patients 3 and 4). Three (21%) of 14 maintained a creatinine
< 200 lmol L1 throughout the acute episode. Only one
patient had a non-specific weakly positive ANA at a titer of
1:80 (patient 6). All aHUS patients had ADAMTS-13 activity
levels > 30% (median 85%, range 47–120%) and no detect-
able ADAMTS-13 inhibitors.
Table 2 Summary of complement analysis of aHUS patients with ADAMTS-13 activity > 10%
Patient
ID Gene
Mutation
identified
C3 (0.65–
1.65 g L1)
C4 (0.16–
0.54 g L1)
FH (0.35–
0.59 g L1)
FI (38–
58 mg L1)
Copies
CFHR1/3
CD46GGAAC
haplotype
copies
CFH H3
haplotype
copies
Mutation
reported
previously
1 CD46 c.286+2T>C
c.286+2T>G*
0.65† 0.14 0.5 39 2 1 0 [7,20,28,45]
2 CD46 c.175C>T;
p.Arg59X
0.56 0.04 0.5 49 1 2 0 [27,28,46]
3 CD46 c.470G>A;
p.Cys157Tyr
0.92† 0.26 0.51 44 2 1 2
4 CD46 c.470G>A;
p.Cys157Tyr
1.31 0.27 0.58 62 2 1 2
5 CD46 c.191G>T;
p.Cys64Phe
1.17 0.17 0.78 84 2 1 0 [29]
6 CFH c.3134-5T>C 0.87 0.23 0.62 53 2 0 2
7 CFH c.3643C>T
p.Arg1215X
0.85 0.31 0.42 73 2 2 1 [1]
8 CFB c.1112A>G
p.Asp371Gly
0.91 0.3 0.67 77 1 1 0
9 C3 c.3023C>T;
p.Ser1008Leu
1.15† 0.34 0.62 60 2 1 1
10 Nil – 1.46 0.31 0.52 66 0 1 0
11 Nil – 0.56 0.03 0.55 52 2 0 2
12 Nil – 0.4 0.09 – – 2 2 1
13 Nil – 0.94 0.24 0.62 50 1 2 0
14 Nil – 1.3 0.32 0.74 77 2 1 1
*Compound heterozygote. †Complement levels measured on convalescent samples. The number of risk alleles for the CFH-H3 haplotype block
that increases the risk of aHUS two- to four-fold [1,47] and the CD46 GGAAC haplotype block that has been associated with a two- to three-
fold increased risk of aHUS [1,48] are shown. Complete deficiency of CFHR1 and CFHR3 has been strongly associated with factor H autoanti-
bodies and aHUS [49–52]. Only patient 10 carried this deletion in homozygosity; however, no factor H autoantibodies were detected in this
study.
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Fig. 1. Serum creatinine and platelet values at presentation in throm-
botic thrombocytopenic purpura (TTP) and atypical hemolytic ure-
mic syndrome (aHUS) patients. Previously suggested cut-off levels
for platelet count (30 9 109 L1) and creatinine of 200 lmol L1 in
aHUS [4] are highlighted. One aHUS patient, who presented with a
platelet count of 115 9 109 1/L and creatinine of 1812 lmol L1, is
censored. Two TTP patients presented with identical platelet counts
and serum creatinine levels.
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Two patients (14%) had transient ischemic attacks: a
72-year-old man with a C3 variant (patient 9) and a 23-
year-old woman with a CFB variant and no preexisting
cardiovascular risk factors (patient 8). Further neurologi-
cal symptoms were reported in the aHUS group: five
(36%) of 14 patients reported a combination of headache
(n = 4), visual disturbance (n = 1) and confusion (n = 1).
Only one aHUS patient required intubation and ventila-
tion at presentation due to cardiorespiratory failure.
Atypical hemolytic uremic syndrome precipitants at
presentation or relapse included pregnancy (n = 2), upper
respiratory tract infection (n = 6), vaccination (n = 2),
and acute abdominal pathology (n = 3), with a case of
appendicitis, pancreatitis, and acute non-infective colitis.
In three cases, there was no identifiable trigger (Table 1).
Three patients had diarrhea at presentation; all were
enterotoxin negative. One patient (patient 1) had a subse-
quent episode of enterotoxin-positive Escherichia coli
diarrhea as a precipitant for relapse. The pregnancy-asso-
ciated aHUS cases presented 3 days post cesarean section
due to an abnormal cardiotocogram (patient 10) and
5 days after cesarean section at 31 weeks for presumed
preeclampsia with nephrotic range proteinuria and a con-
current Pseudomonas bacteremia (patient 7). Subsequent
identification of a pathogenic CFH mutation confirmed
the diagnosis of aHUS in the latter case.
Complement analysis
C3 and C4 levels were both reduced in three (27%) of 11
patients tested during an acute presentation. In 64% (nine
of 14 patients), rare genetic variants in the alternative
complement pathway were identified: five CD46 (one
compound heterozygote, four heterozygotes [two CFH,
one CFB, and one C3]. The variants identified and com-
plement antigenic levels are detailed in Table 2.
Mutation screening in one individual (patient 1)
showed a compound heterozygote CD46 mutation
(c.286+2T>C, c.286+2T>G), which resulted in complete
CD46 deficiency. The c.286+2T>C variant was of mater-
nal origin, while the c.286+2T>G was paternal. Flow
cytometry analysis confirmed absent CD46 expressed on
peripheral blood mononuclear cells. Both parents had
50% CD46 expression with normal serum creatinine. The
CD46 variants Arg59X [27,28] and Cys64Phe [29] have
been reported previously and result in impaired expres-
sion. CD46 expression data on the individuals carrying
the Cys157Tyr genetic variant are not available; however,
the loss of a structurally critical cysteine is highly likely
to result in a non-secreted protein.
The CFH variant p.Arg1215X (patient 7) has been
reported [1] and results in impaired protein secretion.
Analysis of cDNA from the patient with the CFH c.3134-
5T>C genetic variant (patient 6) did not detect any splice
products that differed from the expected transcript
sequence seen in normal control samples. The FH serum
level was normal. A Western blot using a polyclonal anti-
body against FH did not detect any aberrant FH species
(Fig. S1). Thus, from analysis undertaken to date, we
cannot ascribe a functional consequence to this variant.
The CFB variant p.Asp371Gly (patient 8) has not pre-
viously been described and is not reported to be present
in the general population from public mutation databases
(NHLBI GO ESP [National Heart, Lung, and Blood
Institute Grand Opportunity Exome Sequencing Project])
[30]. Polymorphism phenotyping v2 (PolyPhen-2) [31] pre-
dicted that this variant is benign; however, previous in sil-
ico analysis of CFB mutants has demonstrated poor
correlation with functional studies [32]. Structural analysis
using an available crystal structure of complement C3b in
complex with FB demonstrates that this variant resides in
the von Willebrand factor domain of FB [32] in close
proximity to four other aHUS variants where functional
analysis has demonstrated increased activity (Fig. 2A).
The C3 variant p. Ser1008Lys (patient 9) has not previ-
ously been described and is not reported in the NHLBI
GO ESP [30]. PolyPhen-2 predicted that this variant is
probably damaging, although bioinformatic evaluation
should be taken with caution. A co-crystal structure of
CCPs1–4 of FH and C3b demonstrates that the variant
resides in the thioester-containing domain adjacent to
three other functionally significant aHUS-associated
mutations Ala1094Val, Asp1115Asn, and Gln1161Lys
[25] (Fig. 2B).
No patients with FH autoantibody were identified,
although most were screened after TPE or while in clini-
cal remission. At-risk CFH-H3 or CD46GGAAC haplo-
types were identified in all 14 patients tested (Table 2).
Treatment and outcomes
Thirteen of 14 aHUS patients were treated initially with
TPE; one patient (patient 13) had resolving TMA at the
time of transfer and did not require treatment. One patient
(patient 14) developed multiorgan failure and died within
24 h of presentation after receiving corticosteroids and one
TPE. A post mortem study was not performed. Three
patients required renal replacement therapy (RRT) during
episodes of TMA with either peritoneal or hemodialysis on
a total of five occasions (two at relapse) for a duration of
between 4 days and 18 months. Median time from presen-
tation to recovery of platelet count ≥ 150 9 109 L1 was
9 days (range 4–29 days). Only one patient, with a CFB
variant (patient 8), had thrombocytopenia refractory to
TPE, defined by lack of platelet response to 1 week of
TPE, and received eculizumab 13 days after presentation
at a dosage of 900 mg weekly for 3 weeks, with complete
response in both thrombocytopenia and renal function.
Eculizumab was not available for any other patient in this
study at presentation or relapse.
Median follow-up for the aHUS cohort was 2 years
(range 1–28 years). Five of 13 patients had recurrent
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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episodes; all had confirmed complement pathway genetic
abnormalities (three CD46, one CFB, one C3). Two of
the relapses occurred within 1 year of the first episode
(range, 1 month to 8 years after index presentation) and
primarily triggered by viral/bacterial infection or vaccina-
tions (Table 1). The precipitant was unclear in one case
(patient 9), who relapsed just over 1 month after dis-
charge with his initial presentation. The patient with a
CFB mutation (patient 8) relapsed > 1 year after achiev-
ing remission, precipitated by both vaccination and viral
infection, and required an additional two doses of eculi-
zumab. Of interest, she had an uncomplicated pregnancy
between presentations, for which she did not receive eculi-
zumab.
FB
C3b
D371G
K350N
K323E
D279G
F286L
FH
CCP1-4
Q1161K
S1008L
A1094V
D1115N
180°
C3b
A
B
Fig. 2. Location of novel CFB and C3 variants described in this study. (A) The CFB genetic variant Asp371Gly displayed (red sphere) on the
C3b (dark gray): FB (blue) co-crystal structure (Protein Data Base ID code 2XWJ) [53]. Previously reported functionally significant atypical
hemolytic uremic syndrome (aHUS)-associated CFB genetic variants Asp279Gly, Phe286Leu, Lys323Glu, and Lys350Asn (yellow spheres) are
shown residing in the von Willebrand type A domain, inset [54]. (B) An X-ray–derived co-crystal structure of FH/C3b was also used to model
the genetic variant in C3. The location of the Ser1008Leu C3 variant (red sphere) is shown within the co-crystal structure of an FH CCPs1–4
(light gray):C3b (dark gray) complex (Protein Data Base ID code 2WII) [55]. Previously reported functionally significant aHUS-associated C3
genetic variants Ala1094Val, Asp1115Asn, and Gln1161Lys (yellow spheres) are shown inset [54].
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At most recent clinical review, all aHUS patients had
platelet counts above 150 9 109 L1, and 12 of 13 had
normal serum creatinine levels; one patient (patient 6)
had stage 3 chronic kidney disease with a serum crea-
tinine level of 122 lmol L1. Two of 12 patients had per-
sistent proteinuria (one with chronic renal impairment
and one with disease recurrence), and four of 12 patients
required treatment for persistent hypertension. None
required long-term RRT or progressed to ESRF.
Complement analysis in TTP patients
Fourteen TTP patients underwent complement mutation
analysis. The median platelet count was 13 9 109 L1
(range 5–74), and serum creatinine level was
106.5 lmol L1 (61–353). Selection according to severe
phenotypic presentation was based on a combination of
clinical features. Four patients (29%) required intubation
and ventilation at presentation, and two patients had a
stroke. Four patients (29%) had marked renal impair-
ment on presentation with creatinine > 150 lmol L1.
Five patients (36%) had thrombocytopenia refractory to
7 days of TPE. Six (43%) had experienced recurrent
relapses (median of three acute presentations, range 2–6).
All had ADAMTS-13 activity below the lowest level of
quantification (< 5%) with detectable ADAMTS-13 inhi-
bitors. No rare genetic variants were identified in C3,
CFB, CFI, CFH, or CD46 in this cohort.
Discussion
Many studies have shown that TMA patients without
ADAMTS-13 deficiency have significantly higher median
creatinine levels and platelet counts at presentation than
those with confirmed acquired TTP [9,33,34]. Although
our findings were consistent with this, neither of these
laboratory parameters demonstrated adequate specificity
for aHUS, in a cohort of patients of whom most did not
present with oliguric/anuric renal failure. The majority
(13 of 14) of our aHUS patients would be misdiagnosed
based on clinical criteria for differentiation of TTP from
other TMAs suggested in previous publications [4,33].
Coppo et al. reported that either a platelet count
≤ 30 9 109 L1, creatinine level of ≤ 200 lmol L1, or
positive ANA has a 85% positive predictive value and
93.3% negative predictive value for severe ADAMTS-13
deficiency in a large TTP/TMA cohort. Using only plate-
let count and serum creatinine, however, six of 54
patients (11%) with ADAMTS-13 activity > 10% were
incorrectly predicted to have ADAMTS-13 deficiency
based on these clinical variables alone. The intention of
this study, which focused on diagnosis of TTP rather than
aHUS, was not to define TMA classification according to
clinical presentation, and the authors emphasize the need
for pretreatment assessment of ADAMTS-13 activity [33].
Although the aHUS cohort presented here represents a
selected group of patients, referred with suspected TTP,
13 of our 14 aHUS patients would be predicted to have
severe ADAMTS-13 deficiency. It is evident that patients
with both TTP and aHUS present with laboratory values
outside expected limits; therefore, ADAMTS-13 testing is
important for diagnosis and subsequent therapy.
Screening for complement abnormalities in TMA
patients with renal impairment provides valuable diagnos-
tic and prognostic information, although ~ 50% of
patients have no detectable abnormalities [6]. Diagnosis
in these cases remains reliant on clinical features. Pub-
lished studies on aHUS in the acute TMA setting often
define this group by parameters such as serum creatinine
[35]. There are no established assays to measure global
alternative complement pathway activity. In a search for
potential biomarkers, C5a levels were recently shown to
be significantly higher in aHUS than TTP, but there was
significant overlap and no clear cut-off could be suggested
as a diagnostic tool [35]. C3 or C4 levels are not reliable
predictors, confirmed in our aHUS cohort.
In the absence of a rapidly available diagnostic test or
biomarker for aHUS, the presence of ADAMTS-13 defi-
ciency has an important differentiating role in acute
TMAs. In the majority of TTP studies, patients with
ADAMTS-13 activity > 10% had a significantly higher
incidence and severity of renal impairment, a proportion
of whom, in the absence of an identified secondary cause,
may have had aHUS [36]. Many predated knowledge of
alternative complement pathway abnormalities in aHUS,
and none included routine screening for complement
mutations in those without severe ADAMTS-13 defi-
ciency. Cataland et al. reported that ADAMTS-13 levels
< 10% were 100% sensitive and 100% specific for TTP in
a cohort of 57 patients compared with 57 TMA patients
with alternative diagnoses [10]. It has also been demon-
strated that using an ADAMTS-13 activity cut-off of
10% can be safely used to guide TTP therapy [9].
Sixty-four percent of our patients diagnosed with
aHUS had variants in complement genes, consistent with
a prevalence of 44–51% in larger cohorts [5–7]. Given
that complement analysis was performed largely on con-
valescent or post-TPE samples, the presence of FH
autoantibodies may potentially have been missed. Analy-
sis for thrombomodulin [5,37] and diacylglycerol kinase,
epsilon (DGKE) [38] mutations was not undertaken.
DGKE mutations are primarily detected in childhood,
however, and all those presenting at a young age had
mutations identified.
We identified a much higher frequency of isolated
CD46 variants (36% vs. 5–13%) and lower incidence of
CFH variants (14% vs. 20–30%) than were reported in
other studies [5–7,27]. Patients with isolated CD46 muta-
tions are known to have a milder clinical phenotype with
reduced incidence of progression to ESRF (6–19%)
[5,6,27]. The higher proportion of CD46 variants may
account for the better outcomes in our aHUS cohort with
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reduced severity of renal impairment and favorable long-
term outcomes, compared with a 60% incidence of ESRF
or death at 3 years in the largest aHUS cohort [6]. CD46
is a membrane-bound protein where the role of TPE in
treatment is questionable and the majority of patients
with isolated CD46 variants have complete resolution of
disease with or without TPE [5,27].
We identified two CD46-mutated patients (patients 3
and 4), presenting with a relapsing/remitting TMA clini-
cally indistinguishable from TTP, with normal renal func-
tion and ADAMTS-13 levels. Preceding the availability of
ADAMTS-13 assays, both were diagnosed with congeni-
tal TTP, based on their young age of presentation and
relapsing episodes. In similar cases, confirmation of nor-
mal ADAMTS-13 activity should trigger a thorough
assessment for alternative causes of TMA, including com-
plement mutation analysis. Future studies should redefine
the normal ADAMTS-13 ‘TTP’ group and incorporate
molecular diagnostics to a greater extent.
Of particular interest is patient 1 with compound
heterozygous deficiency of CD46. Currently, < 10 patients
have been shown to have complete CD46 deficiency. It is
reported that 50% of those patients have common vari-
able immunodeficiency and recurrent chest infections. It
has been suggested that impaired CD46-Jagged1 crosstalk
is responsible for the recurrent infections in subpopula-
tions of these patients [39]. Our patient had recurrent
upper respiratory tract infections and three episodes of
reported chickenpox in childhood but has not experienced
recurrent infections throughout adulthood.
All except one patient in this cohort received TPE as
the primary treatment with positive clinical outcomes
overall, before eculizumab was available nationally. With
the confirmation of a pathogenic mutation, however,
there is now a precedence to initiate eculizumab at relapse
of an aHUS episode [4,12]. In our cohort, where only one
individual received short intermittent courses of eculizu-
mab, the median time to normalization of platelet count
was 9 days and all except one patient (stage 3 chronic
kidney disease) had complete recovery of renal function.
A brief reintroduction of TPE or eculizumab (in one case)
controlled relapsed disease in all patients. The duration of
terminal complement blockade needs further clarification
with reports suggesting eculizumab may be safely
discontinued in selected patients with appropriate clinical
monitoring [40,41], a finding mirrored by our own
experience.
Activation of the classical and alternative complement
pathways in TTP has been demonstrated in several stud-
ies [42–44], although the relative contribution of comple-
ment to disease pathogenesis has not been fully
elucidated. The TTP cohort presented here represented an
exploratory group selected due to a severe clinical pheno-
type but was not intended for direct comparison with
aHUS patients based on clinical parameters. We did not
identify any congenital or acquired aberrations of the
alternative complement pathway in this select group, sug-
gesting the presence of dual pathologies is exceptional
and that routine screening for complement mutations in
TTP patients with ADAMTS-13 levels < 10% and tran-
sient severe renal impairment is not necessary. It should
be noted, however, that only four TTP patients in this
study presented with creatinine levels > 150 lmol L1.
Larger-scale studies would be required to further validate
these findings.
Conclusion
This aHUS cohort demonstrates the difficulty in clinically
differentiating TTP from complement mediated TMAs.
We highlight that diagnostic differentiation based on pla-
telet count and renal function was insufficient to predict
an underlying complement mutation. This distinction is
increasingly important with the proven efficacy of com-
plement inhibitor therapy in targeting complement activa-
tion in aHUS. In any patient with acute presentation of
idiopathic TMA, identification of an ADAMTS-13 activ-
ity > 10% without detectable anti–ADAMTS-13 autoanti-
bodies necessitates consideration of aHUS. Specifically,
we demonstrate a higher frequency of functionally signifi-
cant CD46 mutations, closely mimicking relapsing/remit-
ting TTP. We have illustrated that remissions can be
associated with TPE in less severe phenotypic presenta-
tions, although with the availability of eculizumab,
patient management is evolving. In a subgroup of patients
with aHUS, continuous therapy is not required to main-
tain disease remission.
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